By Denny Jacob
Arvinas shares dived 40% following results from a Phase 3 clinical trial evaluating vepdegestrant as a treatment for a type of metastatic breast cancer.
Shares were trading around $10.35. The stock is down 61% over the last year.
The biopharmaceutical company in conjunction with Pfizer said the trial did not reach statistical significance in improvement in progression-free survival in the intent-to-treat population.
The trial, however, did meet its primary endpoint in the estrogen receptor 1-mutual population, which the company said demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to fulvestrant.
The two companies in July 2021 announced plans to collaborate on the co-development and co-commercialization of vepdegestrant.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
March 11, 2025 08:37 ET (12:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。